Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Operating Leases: 2019-2024

Historic Operating Leases for Protagonist Therapeutics (PTGX) over the last 5 years, with Dec 2024 value amounting to $10.4 million.

  • Protagonist Therapeutics' Operating Leases fell 21.50% to $8.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year decrease of 21.50%. This contributed to the annual value of $10.4 million for FY2024, which is N/A change from last year.
  • Per Protagonist Therapeutics' latest filing, its Operating Leases stood at $10.4 million for FY2024, which was up 807.62% from $1.1 million recorded in FY2022.
  • In the past 5 years, Protagonist Therapeutics' Operating Leases ranged from a high of $10.4 million in FY2024 and a low of $1.1 million during FY2022.
  • Its 2-year average for Operating Leases is $5.7 million, with a median of $5.7 million in 2022.
  • Data for Protagonist Therapeutics' Operating Leases shows a maximum YoY tumbled of 68.81% (in 2022) over the last 5 years.
  • Yearly analysis of 4 years shows Protagonist Therapeutics' Operating Leases stood at $4.5 million in 2020, then fell by 18.71% to $3.7 million in 2021, then plummeted by 68.81% to $1.1 million in 2022, then reached $10.4 million in 2024.